

Court et al.

all regions and verified that six regions (*PPIEL*, *WDR27*, *HTR5A*, *WRB*, *NHP2L1*, *ERLIN2* loci) are maternally methylated. The DMR we identify within intron 7 of *ERLIN2* appears to be a retro-insertion of the *CXorf56* pseudogene (also known as *LOC728024*) (Fig. 2B,C; Supplemental Fig. S3; Supplemental Table S1).

To confirm that parent-of-origin transcription occurs near these novel imprinted DMRs, we performed allelic RT-PCR in a panel of tissues with primers that discriminate major variant transcripts within each region. This revealed that the DMRs associated with *WDR27*, *NHP2L1*, and *CXorf56* pseudogenes regulate allelic expression in an isoform-specific fashion (Fig. 2B,C; Supplemental Fig. S3; Supplemental Table S1). We detect monoallelic expression of a short alternatively polyadenylated *ERLIN2* transcript which independently substantiates the observation that the generation of retrogenes, primarily from the X chromosome, is a common mechanism for generating imprinted loci (Wood et al. 2008; Kanber et al. 2009). Unfortunately, due to the lack of informative polymorphisms or expression in available heterozygous tissues, we could not perform allelic expression analysis for *PPIEL*, *HTR5A*, and *WRB*.

Histone methylation of H3K4 and DNA methylation are enriched on opposing alleles at imprinted DMRs

GC-rich sequences often coincide with enrichment of H3K4me3, which may act to protect them from de novo methylation (Thomson et al. 2010). The H3K4 demethylase KDM1B (previously known as AOF1) is required for appropriate establishment of maternal germline methylation for a subset of imprinted DMRs in mouse, suggesting that the presence of H3K4 methylation is refractory to DNA methylation deposition in the female germline (Ciccone et al. 2009). By comparing publicly available data sets for ChIP-seq for H3K4me3 and methylated DNA immunoprecipitation (meDIP-seq) from blood and brain, we observe co-enrichment of these opposing epigenetic marks at 89.5% of imprinted DMRs, consistent with differential active and repressive chromatin states on homologous chromosomes. For a limited number of informative regions, we were able to confirm H3K4me3 precipitation on the unmethylated allele (Fig. 3C). In most cases, the methylation profile of maternally methylated DMRs is more closely related to the opposing H3K4me3 profile rather than to the CpG density that classically defines CpG islands (>200 bp, GC content >50%, observed/expected ratio >0.6), with the exception of the *GNAS-XL* DMR. This maternally methylated region was thought to be a single regulatory unit; however, our WGBS and Infinium array data clearly show that it is two separate DMRs, partitioned by an ~200-bp interval of hypermethylation, with the centromeric *GNAS-AS1* (previously known as *NESP-AS*) promoter showing coenrichment for H3K4me3 and DNA methylation, while the *GNAS-XL* side lacks this permissive histone modification (Fig. 3A).

Further interrogation of this data set identified two DMRs associated with multiple promoters with a gradient effect across

the CpG-rich sequences. The *GNAS/GNAS EX1A* CpG island (CpG island 320 in Fig. 3A) is unmethylated on one side, coinciding with H3K4me3, whereas the other is differentially methylated with abundant H3K4me3 and meDIP reads. This pattern was also observed in the bidirectional *HTR5A/HTR5A-AS1* promoter in brain (Fig. 3B), a tissue where these transcripts are most abundant.

Tissue-specific dynamics of imprinted DMRs

The WGBS analysis in leukocytes, brain, and liver confirmed that the extent of allelic methylation at the imprinted DMRs, as defined by the size of the intermediately methylated interval, is highly similar in these somatic tissues (Figs. 1, 4; Table 1). However, some regions were drastically different in the placenta.


By comparing the placental WGBS profile with Infinium β -values for placentae and hydatidiform moles, we observe that the DMRs associated with the maternally methylated *PEG10* and the paternally methylated *H19* are significantly larger in placenta than in somatic tissues. Using standard bisulfite PCR and sequencing, we confirm that the somatically unmethylated *SGCE* promoter, immediately adjacent to the differentially methylated *PEG10* promoter, is methylated on the maternal allele in placenta, while the maternal allele overlapping the *H19* gene body is demethylated (Fig. 4B).

In addition to identifying extended DMRs in the placenta, we also observe complex tissue-specific methylation between somatic tissues and placenta. For example, the *NNAT* and *GNAS-AS1* DMRs, which are maternally methylated in somatic tissue, exhibit hypermethylation in both placenta and hydatidiform mole. Subsequent bisulfite PCR confirmed that these regions are fully methylated in the placenta (Supplemental Fig. S4). Methylation profiling at the *MIR512-1* cluster (also known as *C19MC*)-*ZNF331* locus on chromosome 19 has previously disclosed that the promoter of the pri-miRNA for this miRNA cluster is maternally methylated in placenta, but fully methylated in somatic tissues (Noguer-Dance et al. 2010). We confirm that the *MIR512-1* DMR is unmethylated in hydatidiform moles compared to the partially methylated profile in placenta, with placental WGBS revealing that the DMR is ~5 kb in size, incorporating the promoter CpG island (CpG island 86 in Fig. 4C). However, we notice that the CpG island (CpG island 83 in Fig. 3C) associated with *ZNF331* isoform-3 is hypermethylated on both parental alleles in placenta but is a maternally methylated DMR in somatic tissues. These methylation states dictate complex allelic expression at this locus, with restricted placental-specific paternal expression of the *MIR512-1* pri-miRNA, which does not extend to the *MIR371/2* cluster, and reciprocal imprinting of *ZNF331* (Fig. 4C; Supplemental Table S2).

Novel placental-specific DMRs associated with paternally expressed transcripts

Based on the complex methylation profiles described above, we next investigated if more unknown imprinted DMRs exist solely in

Figure 1. Identification of known imprinted DMRs on the Infinium array platform. (A) Circular karyotype showing the difference of methylation for three consecutive probes for reciprocal UPD leukocyte samples. Red dots indicate a minimal difference of 0.3 in Infinium probe β -values (>30% absolute methylation value) for regions with maternal methylation, and blue dots indicate the same for paternal methylation. Known DMRs are indicated. (B) Heat map of the Infinium probes located within known imprinted DMRs in reciprocal genome-wide UPD samples and various somatic tissues. (C) WGBS and Infinium array methylation profiles of the *ZNF597* locus with bisulfite PCR confirmation of the novel maternally methylated DMR and its position in relation to the somatic paternally methylated promoter region. Vertical gray lines in the WGBS tracks represent the mean methylation value for individual CpG dinucleotides calculated from multiple data sets, with the light gray lines representing the mean + standard deviation. Infinium methylation values for normal tissues are represented by black dots, with values for the genome-wide UPDs (average pUPD in blue and mUPD in red) superimposed on the leukocyte methylation track. The error bars associated with the Infinium array probes represent the standard deviation of multiple biological samples. The PCR confirmation in placenta, kidney, and leukocyte-derived DNA was performed on heterozygous samples. Each circle represents a single CpG dinucleotide on a DNA strand. (●) Methylated cytosine, (○) unmethylated cytosine. Each row corresponds to an individual cloned sequence.



placental tissues, as highlighted by the *MIR512-1* and *GPR1-AS* DMRs (Noguer-Dance et al. 2010; Kobayashi et al. 2013).

We performed a screen for partially methylated regions present solely in our placenta WGBS data set using our sliding window approach ($0.25 < \text{mean of } 25 \text{ CpG} \pm 2 \text{ SD} < 0.75$). This identified 722 windows, of which 520 mapped to CpG islands. These results confirm that placental-derived DNA is significantly less methylated when compared to other tissues (Schroeder et al. 2013) and that this genome-wide lower methylation is not restricted to repetitive elements as previously described (Ehrlich et al. 1982; Fuke et al. 2004), but occurs across a large portion of the genome.

Of these partially methylated placenta domains identified by WGBS, 44 regions were ~50% methylated in placenta, with extreme methylation in hydatidiform moles using the Infinium array (average β -value for three consecutive probes >0.8 indicative of paternal methylation or <0.2 indicative of maternal methylation), and showed no evidence of allelic methylation in somatic tissues. Using standard bisulfite PCR, we assessed the allelic methylation profile of all regions in placental DNA samples. This revealed that the promoters of *N4BP2L1*, *DCAF10*, *PDE4D*, *FAM196A*, *RGMA*, *AGBL3*, *MCCCL1*, *ZC3H12C*, *DNMT1*, *AIM1*, *ZNF396*, *FAM20A*, *GLIS3*, and *LIN28B* are methylated on the maternal allele (Fig. 4D; Supplemental Fig. S5; Supplemental Table S2). In addition, we identified a 2.8-kb region of intermediate methylation overlapping an alternative promoter of the paternally expressed *ZFAT* gene in the placental WGBS data set (Supplemental Fig. S5). Using allelic-specific bisulfite PCR, we confirm that the methylation is confined to the maternal chromosome at this locus. To determine if these regions of maternal methylation influence transcription, allelic RT-PCR experiments were carried out. Paternal expression of eight of these genes was verified, with biallelic expression in somatic tissues (Fig. 4D; Supplemental Fig. S5; Supplemental Table S2) consistent with recent allelic expression screens in term placenta (Yuen et al. 2011; Barbaux et al. 2012).

Mammalian conservation of novel imprinted domains

To determine if the previously unrecognized imprinted domains are conserved throughout evolution, we assessed their allelic methylation and expression in mice, using a reciprocal cross between mouse strains. Bisulfite PCR targeting of orthologous regions failed to identify evidence of differential methylation in embryonic day E9.5–14.5 embryos or extra-embryonic tissues. Subsequent allelic RT-PCRs revealed that all murine transcripts orthologous to the novel ubiquitous and placental-specific imprinted transcripts are equally expressed from both parental alleles when detected (Supplemental Figs. S6, S7). This suggests that these new imprinted domains arose less than ~80 million years ago after the divergence of mice and humans or that selection pressures over this period have resulted in a loss of imprinted regulation of these genes in mice. It has been previously reported that imprinting in the placenta dif-

fers between human and mouse, mainly due to the lack of imprinting of genes which require repressive histone modifications for allelic silencing in humans (Monk et al. 2006). Contrary to previous reports, our results show that humans have evolved more loci subject to this form of transcriptional regulation in placenta, due to the evolutionary acquisition of loci with parent-of-origin methylation. This is endorsed by the low discovery rate of novel imprinted transcripts in RNA-seq screens of mouse placenta (Okada et al. 2011).

Differential methylation at ubiquitously imprinted loci and placental-specific domains may differ in their genetic origin

An essential step toward understanding the establishment of the germline imprint signal is to determine if the parent-of-origin methylation observed in somatic tissues is derived from the germline. Determining the methylation profiles in human gametes and during the early preimplantation stages of embryonic development is technically and ethically challenging. To circumvent these difficulties, we have used a combination of mature gametes and in vitro models to represent human gametes of both sexes and preimplantation embryos. For analysis during gametogenesis in males, we used mature sperm. We compared publicly available WGBS data sets from sperm and human embryonic stem (hES) cells that represent the inner cell mass of the blastocysts (Lister et al. 2009; Molaro et al. 2011) with our own Infinium array profiles for sperm, parthenote-derived hES cell lines (phES), and hES cell lines generated from both six-cell blastomeres (Val10B) and the inner cell mass of blastocysts (SHEF cell lines). Despite the phES cell lines having undergone reprogramming during blastocyst development, they have previously been shown to retain maternal hypermethylation at the limited imprinted loci assessed, suggesting that they are ideal surrogates for assessing the methylation profiles of imprinted DMRs in mature oocytes (Mai et al. 2007; Harness et al. 2011).

A comparison of Infinium β -values between sperm and phES cells for the human sequences orthologous to the mouse germline DMRs (Kobayashi et al. 2012) revealed that 19/22 are conserved. The novel ubiquitous DMRs we identify are also hypermethylated in phES cells and unmethylated in sperm, suggesting that the majority of imprinted DMRs, with the exception of *IGF1R*, are primarily marked in the gametes (Fig. 5A; Supplemental Fig. S8). In addition, we confirm that the IG-DMR within the chromosome 14 domain is $>80\%$ – 90% methylated in the sperm WGBS data set, in line with previous reports (Geuns et al. 2007). We were particularly intrigued to observe that all placental-specific DMRs, with the exception of *ZFAT*, *GPR1-AS*, and *MIR512-1*, do not inherit methylation from the gametes and are devoid of methylation in hES cells (Fig. 5A). These data provide preliminary evidence to suggest that, following gametogenesis, parental alleles at some loci retain a nonequivalency that is not associated with DNA methylation.

Figure 2. Identification and characterization of allelic methylation and expression of novel imprinted loci. Circular karyotype showing the position of common regions of intermediate methylation in the leukocyte, brain, and liver WGBS data sets, as identified using a 25 CpG sliding window approach ($0.25 < \text{mean} \pm 1.5 \text{ SD} < 0.75$). Red ticks represent sites of intermediate methylation common to all tissues, whereas black ticks identify those present in only one or two pairwise comparisons. The position of known imprinted DMRs are shown. (B) Identification of a novel maternally methylated DMR within the *WDR27* locus by WGBS and Infinium array analysis. Vertical gray lines in the WGBS tracks represent the mean methylation value for individual CpG dinucleotides calculated from multiple data sets, with the light gray lines representing the mean + standard deviation. Infinium methylation values for normal tissues are represented by black dots, with values for the genome-wide UPDs (average pUPD in blue and mUPD in red) superimposed on the leukocyte methylation track. The DMR was confirmed using standard bisulfite PCR on heterozygous DNA samples and orchestrates paternal expression of *WDR27* isoform 2. The asterisk (*) in the sequence traces shows the position of the polymorphic base. (C) Imprinting of *ERLN2* isoform 1 in leukocytes as a consequence of the retrotransposition of the X chromosome-derived *CXorf56* pseudogene into the locus.




Figure 3. H3K4me3 chromatin profile and DNA methylation at imprinted loci. (A) Map of the human *GNAS* locus on chromosome 20 with the H3K4me3 and meDIP signatures in brain and leukocytes at the DMRs identified in the WGBS and Infinium array analysis. Infinium methylation values for normal leukocytes (black dots), with values for the genome-wide pUPD (blue) and mUPD (red) superimposed on the leukocyte WGBS track. Similarly, Infinium methylation values for two normal brain samples are shown as black and gray dots. The light and dark gray peaks in the meDIP and ChIP-seq panels represent two independent biological replicates compared to input (black peaks). The bars under the CpG islands, as identified in the UCSC Genome Browser, show the location of the bisulfite PCR amplicons. (B) The gradient DMR identified at the *HTR5A* promoter. The samples used for the WGBS, Infinium array, and ChIP are the same as in A. The independent methylation pattern on either side of the bidirectional promoter interval was confirmed using standard bisulfite PCR and sequencing. (C) Allelic ChIP for H3K4me3 reveals predominant enrichment of this histone modification on the unmethylated allele of the *H19* ICR, *SNURF* ICR, *NNAT*, and *MCTS2P* DMRs. The asterisk (*) in the sequence traces shows the position of the polymorphic base.




Figure 4. (Legend on next page)

Therefore, in the female germline, as represented by the phES cells, a subset of imprinted loci retain their identity in the absence of methylation, suggesting that additional epigenetic mechanisms mark these regions for maternal methylation during trophoblast differentiation (Fig. 5A).

For the majority of DMRs for which allelic methylation was observed in the somatic tissues (80%), the genomic interval showing methylation differences between sperm and phES cells is larger than the allelic DMRs in hES cells and somatic tissues (Fig. 5B,C). In the case of maternally methylated DMRs, we observe that these regions are flanked by fully methylated intervals in both gametes, and that these DMRs are observed as regions devoid of methylation in the sperm genome. Interrogation of ChIP-seq data sets for nucleosomes containing the histone modifications revealed that the majority of unmethylated DMR regions in sperm are enriched for H3K4me3 containing nucleosome fractions. Our analysis indicates that the size of the unmethylated region in sperm is therefore associated with nucleosome occupancy, rather than protamines. Notably, the maternally methylated germline DMR overlapping the *NNAT* promoter is ~4 kb, as defined by full methylation in phES cell and the H3K4me3 enriched DNA unmethylated region in sperm. This region contracts to an ~1.5-kb region of maternal methylation after preimplantation reprogramming as represented by blastocyst-derived hES cells and somatic tissue profiles (Fig. 5C; Supplemental Fig. S9A showing the contraction at the *NAP1L5* locus). Such resizings are also observed in mouse (Tomizawa et al. 2011), suggesting that imprinted DMRs are not totally protected from genome-wide demethylation during the oocyte to embryo transition. We speculate that the larger regions of differential methylation dictated by the gametes, in combination with protective factors, ensure that they survive reprogramming.

In addition, we also observe other subtle differences in germline-derived methylation profiles. For example, the two sides of the *GNAS-XL* DMR that we show to have independent H3K4 methylation profiles from each other behave differently in the germline, with the *GNAS-AS1* side being a somatic DMR only, but the *GNAS-XL* side being methylated in phES cells and hypomethylated in sperm (Supplemental Fig. S4). Lastly, we identified a dynamic relocalization of methylation at the *FAM50B* DMR during preimplantation development. The 1.2-kb promoter of this imprinted retrogene is methylated on the maternal allele in somatic tissues but is completely unmethylated in phES cells and hES cells derived from six-cell embryos, and has been shown to be unmethylated in sperm (Nakabayashi et al. 2011). However, we do find that allelic methylation is conferred during preimplantation development, at a point between the six-cell stage and blastocyst development. In fact, the ~1-kb regions flanking the promoter (labeled 1 and 3 in Supplemental Fig. S9B) show strongly opposing methylation profiles, with the sperm being unmethylated and phES cells methylated, which then become fully methylated on

both alleles immediately after fertilization, leaving allelic methylation over the promoter itself.

Discussion

Differentially methylated regions between the parental alleles are essential for genomic imprinting and development. In this study, we have performed a comprehensive survey of methylation in various human tissues, uncovering all known imprinted DMRs as well as 21 novel loci, which we demonstrate wherever possible regulate imprinted transcription. Our present work demonstrates that the human genome contains a significantly larger number of regions of parent-of-origin methylation than previously thought. The identification of imprinted domains has traditionally been performed in mouse by utilizing gynogenetic and androgenetic embryos, mice harboring regions of uniparental disomies, or highly polymorphic inbred strains (Cooper and Constância 2010). These embryos have been subjected to expression-based screens, including RNA-seq (Gregg et al. 2010; Okae et al. 2011), and genome-wide methylation techniques (Hayashizaki et al. 1994; Kelsey et al. 1999; Hiura et al. 2010). By relying on the confirmation of the evolutionarily conserved expression of the human orthologs, imprinted genes specific to higher primates and humans would have been missed. We have utilized high-throughput bisulfite analysis from in vitro models of gametes and early embryos, and somatic and placental DNA, to characterize the developmental dynamics of imprinted methylation coupled with allelic expression analysis of nearby transcripts. This analysis reveals that 30 regions of parentally inherited differential methylation are observed in humans but not mice. Conversely, we also show that the DMRs associated with *Cdkn1c*, *Rasgrf1*, the *Igf2r* promoter, *Impact*, *Slc38a4*, and *Zrsr1* (previously known as *U2af1-rs1*) imprinted transcripts in mouse do not exhibit allelic methylation in humans (Xie et al. 2012).

Recently, a novel mechanism has been described in which differences in germline methylation can give rise to tissue-specific DMRs in mouse (Proudhon et al. 2012). The *Cdh15* DMR inherits methylation from the oocyte and maintains this parental allelic methylation during in utero development and in adults, with the exception that the paternal allele gains methylation in various brain regions. Therefore, the intragenic *Cdh15* DMR is conserved during adulthood, but in a tissue-specific manner. In humans, the *CDH15* locus does not exhibit allelic DNA methylation in any tissue (data not shown), suggesting that this tissue-specific methylation profile might be limited to mice. We cannot rule out the existence of temporally regulated tissue-specific imprinted DMR in humans, since our samples were derived from adults, and therefore any imprinted DMRs specific to the fetal period would be missed.

Our study reveals the power of combining WGBS and Infinium HumanMethylation450 BeadChip arrays to identify novel imprinted DMRs. We have previously combined reciprocal genome-wide UPD samples and the Infinium HumanMethylation27

Figure 4. The methylation profiles of imprinted loci in placenta compared to somatic tissues. The placenta- and leukocyte-derived WGBS and Infinium array profiles at the (A) *PEG10* and (B) *H19* loci. Infinium methylation values for normal leukocytes (black dots), with values for the genome-wide pUPD (blue) and mUPD (red) superimposed on the leukocyte WGBS track. Similarly, Infinium methylation values for normal placenta (black dots) and hydatidiform mole (blue dots) are overlaid on the placental WGBS track. The error bars associated with the Infinium array probes represent the standard deviation of multiple biological samples. Bisulfite PCR analysis was used to confirm the tissue-specific methylation profiles. (C) Complex tissue-specific allelic methylation and expression patterns at the *ZNF331-MIR512* cluster locus on chromosome 19. The *ZNF331* sequence traces represent the RT-PCR products from leukocytes, whereas both the *MIR512-1* cluster and *MIR371/2* are from placenta. (D) A placental-specific imprinted DMR identified using the placenta-derived WGBS and Infinium array data sets. The methylation profiles were confirmed using standard bisulfite PCR on heterozygous DNA samples with allelic RT-PCR performed on placental biopsies. The results confirm that the region of maternal methylation overlapping the *AGBL3* promoter dictates paternal expression of this gene in placenta.




Figure 5. (Legend on next page)

BeadChip arrays to identify imprinted loci (Nakabayashi et al. 2011). All new regions of ubiquitous imprinted methylation identified in the current screen are associated predominantly with type II Infinium probes and were not present on previous array platforms. Of the placental-specific DMRs, only those associated with *DNMT1*, *AIM1*, and *MCCCI* have been previously described (Yuen et al. 2011; Das et al. 2013). Intriguingly, the somatic promoter of *Dnmt1* is differentially methylated between sperm and oocytes but is lost during preimplantation development (Smallwood et al. 2011; Kobayashi et al. 2012). Two of these placental-specific DMRs are associated with type I Infinium probes and were previously discovered using the Infinium HumanMethylation27 BeadChip arrays with DNA derived from diandric and digynic triploid placental samples (Yuen et al. 2011).

Our data provide the first direct evidence in humans that the differential methylation associated with imprinted genes is dynamically regulated upon fusion of the gametes at fertilization. Most maternally methylated DMRs are surrounded by regions of complete methylation in both gametes, and as in mice, the DMRs are clearly observed as unmethylated islands in the sperm genome. These unmethylated intervals are often more extensive in sperm compared to somatic tissues, suggesting that resizing occurs during embryonic transition. It was recently reported that nucleosomes are retained at specific functional regions in sperm chromatin and are refractory to protamine exchange (Hammoud et al. 2009). These sperm-derived histones are enriched for H3K4me3, a permissive modification that is mutually exclusive with DNA methylation, implicating these H3K4me3 regions in the maintenance of the unmethylated state in the male germline.

Imprints are distinguishable from other forms of gametic methylation as they survive the reprogramming that initiates immediately upon fertilization (Smallwood et al. 2011; Kobayashi et al. 2013; Proudhon et al. 2012). By comparing the profiles of sperm, phES, and conventional hES cells along with somatic tissues, we present evidence that most maternally methylated DMRs are not completely refractory to reprogramming, as highlighted by the substantial resizing of the paternally derived unmethylated alleles. These data are consistent with the notion that the cores of imprinted DMRs are protected from Tet-associated demethylation by recruiting heterochromatic factors such as ZFP57 and DPPA3 (also known as STELLA or PGC7) (Nakamura et al. 2007; Li et al. 2008). Similar mechanisms could also act to protect the core of the unmethylated paternal alleles from methylation.

A search for the mouse ZFP57 recognition sequence (TGCC^{met}GC) identified numerous binding sites within the ubiquitous imprinted DMRs that may be involved in protecting methylation during preimplantation reprogramming (Quenneville et al. 2011). It is currently unknown if this hexonucleotide motif is bound by ZFP57 in human cells, but patients with mutated ZFP57 lack DNA binding capacity in *in vitro* EMSA studies (Baglivo et al. 2013).

There are significantly fewer ZFP57 sequence motifs in the placental-specific DMRs compared to the ubiquitous DMRs that inherit methylation from the germline ($P < 0.05$, Student's *t*-test), with 14/17 placental-specific DMRs being unmethylated and not associated with H3K9me3 in hES cells (Supplemental Fig. S10). These data further support our hypothesis that a novel imprinting mechanism occurs in the placenta, which is one of the first examples of methylation-independent epigenetic inheritance in mammals. In support of our observations, Park and colleagues (Park et al. 2004) generated a *H19* ICR knock-in at the *Afp* locus which was de novo methylated around gastrulation, implying that *H19* ICR is differentially marked in the gametes by a mechanism other than methylation. However, it is unknown if this mechanism also occurs at the endogenous *H19* locus. In our examples of placental-specific DMRs, the epigenetic mark inherited from the oocyte is currently unknown, but must be recognized by the de novo methylation machinery during early trophoblast differentiation, since we observe maternal methylation in term placenta. Certain histone methylation states are reported to recruit DNMTs (Dhayalan et al. 2010; Zhang et al. 2010). Since various post-translational modifications of histone tails have been shown to be present at imprinted loci, specifically in the placenta independent of DNA methylation (Umlauf et al. 2004; Monk et al. 2006), we are led to suggest one inviting hypothesis: A histone modification confers the "imprint" at these novel placental-specific imprinted loci. Alternatively, the DNMTs may be recruited to these loci by a specific, yet to be identified, transcription factor expressed during early trophoblast differentiation.

In line with other well-characterized imprinted genes in the placenta, the placental-specific imprinted transcripts may also exert supply-and-demand forces between the developing fetus and mother, ultimately influencing fetal adaptation in utero, which if disrupted may have long-term consequences on health many decades after delivery (Constância et al. 2004). Our observation of imprinting of the somatic promoter of *DNMT1* in placenta may therefore assist in this process. In addition, numerous studies have also suggested that children born as a result of assisted reproductive technologies (ART), including ovarian stimulation, *in vitro* fertilization, and intra-cytoplasmic sperm injections, have a higher risk of diseases with epigenetic etiologies, including imprinting disorders (Amor and Halliday 2008). In a clinical context, the placenta-specific imprinted loci may be prone to epigenetic instability during ART, as the first differentiation step that results in the trophoblast occurs when the developing blastocysts are in culture.

By utilizing genome-wide methylation profiling at base-pair resolution, we have catalogued regions of parentally inherited methylation associated with imprinted regions and highlighted all differences between somatic and placental tissues. Further studies of these loci will provide insight into the causes of epigenetic ab-

Figure 5. Methylation in gametes, hES cells, and somatic tissues. (A) Heat maps for Infinium probes mapping within all ubiquitous (*left*) and placental-specific (*right*) imprinted DMRs in sperm and phES cells reveal the germline acquisition of methylation. (B) Methylation contour plots from WGBS data sets for all maternally methylated DMRs reveal that the extent of the intermediately methylated regions associated with imprinted DMRs are extremely consistent between somatic tissues and significantly larger in sperm. (C) Methylation profiles at the *NNAT* DMR determined by WGBS, Infinium array, and meDIP-seq data sets in leukocytes, sperm, phES cells, and hES cells, along with the H3K4me3 CHIP-seq reads for hES cells and sperm. The gray and black dots in the second panel represent Infinium probe methylation in hES cell lines derived from six-cell blastomeres (Val10B) and blastocytes (SHEF5), respectively. The gametic WGBS methylation profile is derived from sperm, with Infinium probe methylation values for sperm and phES cells represented by blue and red dots. The graphic shows the extent of the differentially methylated regions in somatic tissues and between sperm and phES cells. The error bars associated with the Infinium array probes represent the standard deviation of the two sperm samples and four independent phES cell lines. The H3K4me3 CHIP-seq data is from sperm. The methylation profiles were confirmed using standard bisulfite PCR and sequencing.

errations associated with imprinting disorders and may be relevant to the epigenetic causes of common diseases.

Methods

Tissue samples and cell lines

Peripheral blood was obtained from healthy volunteers or from the umbilical cord of newborns for which we obtained matched placental biopsies. These samples were collected at the Hospital St. Joan De Deu (Barcelona, Spain) and the National Center for Child Health and Development (Tokyo, Japan). All placenta-derived DNA samples were free of maternal DNA contamination based on microsatellite repeat analysis. The brain samples were obtained from BrainNet Europe/Barcelona Brain Bank. Ethical approval for this study was granted by the Institutional Review Boards at the National Center for Child Health and Development (project 234), Saga University (21-5), Hamamatsu University School of Medicine (23-12), Hospital St. Joan De Deu Ethics Committee (35/07), and Bellvitge Institute for Biomedical Research (PR006/08). Written informed consent was obtained from all participants.

The hES (SHEF 3, 5, 6 and Val10B) and parthenogenetically activated oocyte (LLC6P, LLC7P, LLC8P, and LLC9P) cell lines were used because they were epigenetically stable at imprinted loci (with the exception of *NNAT* LOM and *GNAS* GOM in LLC7P; LOM of *PEG3* in Val10B; GOM of *MCTS2P* in SHEF3) and grown as previously described (Harness et al. 2011). Ethical approval for the study of these cells was granted by the Bellvitge Institute for Biomedical Research Ethics Committee (PR096/10) and Comité Ético de Investigación Clínica (CEIC) del Centro de Medicina Regenerativa de Barcelona-CMR[B] (28/2012) and complied with the legal guidelines outlined by the Generalitat de Catalunya El conseller de Salut.

Wild-type mouse embryos and placentae were produced by crossing C57BL/6 (B) with *Mus musculus molosinus* (JF1) or *Mus musculus castaneus* (C) mice. Mouse work was approved by the Institutional Review Board Committees at the National Center for Child Health and Development (approval number A2010-002). Animal husbandry and breeding were conducted according to the institutional guidelines for the care and the use of laboratory animals. DNA and RNA extractions and cDNA synthesis were carried out as previously described (Monk et al. 2006).

Characterization of the genome-wide UPD samples

Genomic DNA was isolated from two previously described genome-wide paternal UPD cases with BWS features (Romanelli et al. 2011) and two newly identified individuals, at Saga University, as well as one genome-wide maternal UPD with a SRS phenotype (Yamazawa et al. 2010). Each of these cases had undergone extensive molecular characterization to confirm genome-wide UPD status and the extent of mosaicism. We used DNA isolated from lymphocytes, as these samples had minimal contamination of the biparental cell lines. The genome-wide pUPD samples had 9, 11, 9, and 2% biparental contribution, whereas the genome-wide SRS sample had 16%. In addition, four hydatidiform moles were collected by the National Center for Child Health and Development.

Genome-wide methylation profiling

We analyzed six publicly available methylomes, including those derived from CD4+ lymphocytes (GSE31263) (Heyn et al. 2012), brain (GSM913595) (Zeng et al. 2012), the H1 hES cell line (GSM432685, GSM432686, GSM429321, GSM429322, GSM429323), and sperm

(GSE30340). In addition, we generated three additional tissue methylomes using WGBS for brain, liver, and placenta. WGBS libraries were generated as previously described (Heyn et al. 2012).

We also generated methylation data sets using the Illumina Infinium HumanMethylation450 BeadChip arrays, which simultaneously quantifies ~2% of all CpG dinucleotides. Bisulfite conversion of 600 ng of DNA was performed according to the manufacturer's recommendations for the Illumina Infinium Assay (EZ DNA methylation kit, Zymo). The bisulfite-converted DNA was used for hybridization following the Illumina Infinium HD methylation protocol at genomic facilities of the Cancer Epigenetics and Biology Program (Barcelona, Spain) or the National Center for Child Health and Development. Data was generated for the genome-wide UPDs (4× pUPD, 1× mUPD), two brain, one liver, one muscle, one pancreas, two sperm, four hydatidiform moles, four term placentae, four pHES cell lines, and the four hES lines. In addition, we used three leukocyte data sets from GSE30870.

Data filtering and analysis

For WGBS, the sequence reads were aligned to either strand of the hg19 reference genome using a custom computational pipeline (autosomal CpGs with at least five reads: brain sample, 190,314,071 aligned unique reads, 83% coverage; liver sample, 778,733,789 aligned unique reads, 96.6% coverage; placenta sample, 319,362,653 aligned unique reads, 89.6% coverage). The methylation level of each cytosine within CpG dinucleotides was estimated as the number of reads reporting a C, divided by the total number of reads reporting a C or T. For the identification of intermediately methylated regions associated with imprinted DMRs, we performed a sliding window approach in which the methylation of 25 CpGs was averaged after filtering for repetitive sequences. The location of these sequences was taken from the UCSC sequence browser. An interval was considered partially methylated if the average methylation was $0.25 < \text{mean} \pm 1.5 \text{ SD} < 0.75$.

For the Illumina Infinium HumanMethylation 450 BeadChip array, before analyzing the data, we excluded possible sources of technical biases that could influence results. We applied signal background subtraction, and inter-plate variation was normalized using default control probes in BeadStudio (version 2011.1.1 Infinium HD). We discarded probes with a detection *P*-value >0.01. We also excluded probes that lacked signal values in one or more of the DNA samples analyzed. In addition, we discarded 16,631 probes as they contained SNPs present in >1% of the population (dbSNP 137). Lastly, prior to screening for novel imprinted DMRs, we excluded all X chromosome CpG sites. In total, we analyzed 442,772 probes in all DNA samples. All hierarchical clustering and β -value evaluation was performed using the Cluster Analysis tool of the BeadStudio software.

In-house R-package scripts were used to evaluate the average methylation of three contiguous Infinium probes. To identify regions with potential allelic methylation, we screened the reciprocal genome-wide UPDs for three consecutive probes with an average β -value difference greater than 0.3 (Limma linear model $P < 0.05$):

$$\left| \frac{1}{3} \sum_{n=0}^2 pUPD_n - \frac{1}{3} \sum_{n=0}^2 mUPD_n \right| > 0.3.$$

With the condition that the average of three consecutive probes for the normal leukocytes is between the values for the reciprocal genome-wide UPDs:

$$\left\{ \begin{array}{l} \text{if } \frac{1}{3} \sum_{n=0}^2 pUPDs_n > \frac{1}{3} \sum_{n=0}^2 mUPD_n \\ \text{then } \frac{1}{3} \sum_{n=0}^2 pUPDs_n > \frac{1}{3} \sum_{n=0}^2 Leukocytes_n > \frac{1}{3} \sum_{n=0}^2 mUPD_n \\ \text{if } \frac{1}{3} \sum_{n=0}^2 mUPD_n > \frac{1}{3} \sum_{n=0}^2 pUPDs_n \\ \text{then } \frac{1}{3} \sum_{n=0}^2 mUPD_n > \frac{1}{3} \sum_{n=0}^2 Leukocytes_n > \frac{1}{3} \sum_{n=0}^2 pUPDs_n. \end{array} \right.$$

The final condition was that the average of three consecutive probes for normal leukocytes is within the 0.25–0.75 intermediate methylation range:

$$0.25 > \frac{1}{3} \sum_{n=0}^2 Leukocytes_n > 0.75.$$

Genotyping and imprinting analysis

Genotypes of potential SNPs identified in the UCSC Genome Browser (hg19) were obtained by PCR and direct sequencing. Sequence traces were interrogated using Sequencher v4.6 (Gene Codes Corporation) to distinguish heterozygous and homozygous samples. Heterozygous sample sets were analyzed for either allelic expression using RT-PCR or bisulfite PCR, incorporating the polymorphism within the final PCR amplicon so that parental alleles could be distinguished (for primer sequence, see Supplemental Table S3).

Bisulfite PCR

Approximately 1 μ g DNA was subjected to sodium bisulfite treatment and purified using the EZ DNA Methylation-Gold kit (Zymo), and was used for all bisulfite PCR analysis. Approximately 2 μ L of bisulfite-converted DNA was used in each amplification reaction using Immolase Taq polymerase (Bioline) at 35–45 cycles, and the resulting PCR product cloned into pGEM-T easy vector (Promega) for subsequent subcloning and sequencing (for primer sequence, see Supplemental Table S3). For the confirmation of an imprinted DMR, we analyzed a minimum of three heterozygous samples and, where possible, two different tissues.

Chromatin immunoprecipitation (ChIP)

We analyzed publicly available H3K4me3 ChIP-seq and meDIP-seq data sets, including those derived from lymphocytes (GSM772948, GSM772836, GSM772916, GSM543025, GSM613913), brain (GSM806943, GSM806935, GSM806948, GSM669614, GSM669615), and the H1 hES cell line (GSM409308, GSM469971, GSM605315, GSM428289, GSM456941, GSM543016). For H3K9me3 in hES cells, we used GSM450266. In addition, we used the sperm ChIP-seq data set for H3K4me3 as a direct measure of nucleosome occupancy (GSM392696, GSM392697, GSM392698, GSM392714, GSM392715, GSM392716) (Hammoud et al. 2009).

The confirmation of allelic H3K4me3 in leukocytes or lymphoblastoid cell lines was performed as previously described (Iglesias-Platas et al. 2013). Briefly, 100 μ g of chromatin was used for an immunoprecipitation reaction with Protein A agarose/salmon sperm DNA (16-157, Millipore) and a H3K4me3 (07-473, Millipore). Each ChIP was performed in triplicate alongside a mock immunoprecipitation with an unrelated IgG antiserum, and a 1% fraction of the input chromatin was extracted in parallel. Levels of immunoprecipitated chromatin at each specific region were determined by qPCR using SYBR Green (Applied Biosystems) carried out on the Applied Biosystems 7900 Fast real-time

PCR system (for primer sequence, see Supplemental Table S3). Each PCR was run in triplicate and protein binding was quantified as a percentage of total input material.

Data access

The data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE52578.

List of affiliations

¹Imprinting and Cancer Group, Cancer Epigenetic and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Hospital Duran i Reynals, 08908 Barcelona, Spain; ²Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan; ³Servicio de Neonatología, Hospital Sant Joan de Déu, Fundació Sant Joan de Déu, 08950 Barcelona, Spain; ⁴Department of Systems Biomedicine, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan; ⁵Fundación IVI-Instituto Universitario IVI-Universidad de Valencia, INCLIVA, 46980 Paterna, Valencia, Spain; ⁶Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, United Kingdom; ⁷Reeve-Irvine Research Centre, Sue and Bill Gross Stem Cell Research Center, Department of Anatomy and Neurobiology, School of Medicine, University of California at Irvine, Irvine, California 92697, USA; ⁸Cancer Epigenetics Group, Cancer Epigenetic and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Hospital Duran i Reynals, 08908 Barcelona, Spain; ⁹Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan; ¹⁰Instituto de Genética Médica y Molecular, CIBERER, IDIPAZ-Hospital Universitario La Paz, Universidad Autónoma de Madrid, 28046 Madrid, Spain; ¹¹Division of Molecular Genetics and Epigenetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan; ¹²Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08036 Barcelona, Catalonia, Spain; ¹³Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain; ¹⁴Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

Acknowledgments

We thank S. Morán at PEBC-IDIBELL for performing the methylation array hybridization and S. Sayols and H. Heyn for bioinformatics assistance. We also thank P. Arnaud and J. Frost for stimulating discussions and helpful comments. This work was partially funded by grants from the Fundació La Marató de TV3 (grant no. 101130 to D.M. and P.L.); Spanish Ministerio de Educación y Ciencia (BFU2011-27658 to D.M.); JST/CREST and the Health and Labour Sciences Research Grant (Nanbyo-Ippan-003 to K.H.); the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#22249010) and the National Center for Child Health and Development (#24-3) to K.N. D.M. is a Ramon y Cajal research fellow. Finally, we would like to thank all the patients and their families for participating in this project.

References

Amor DJ, Halliday J. 2008. A review of known imprinting syndromes and their association with assisted reproduction technologies. *Hum Reprod* 23: 2826–2834.